Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy.
Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy.
复制标题
免疫功能低下宿主中单纯疱疹病毒引起的感染：自然史和局部阿昔洛韦治疗。
DOI：
10.1093/infdis/150.3.323
复制
发表时间：
1984
期刊：
影响因子：
--
通讯作者：
Soong,SJ
中科院分区：
文献类型：
--
作者：
Whitley,RJ;Levin,M;Barton,N;Hershey,BJ;Davis,G;Keeney,RE;Whelchel,J;Diethelm,AG;Kartus,P;Soong,SJ
在一项局部阿昔洛韦治疗的双盲、安慰剂对照研究中，对63例免疫功能低下的单纯疱疹病毒感染患者进行了评价; 33例患者接受阿昔洛韦治疗，30例患者接受安慰剂治疗。两组患者在年龄、种族、性别、基础疾病、既往化疗以及病变部位、大小和持续时间方面平衡。接受阿昔洛韦治疗的患者在病毒清除（P= 0.0006）、疼痛缓解（P= 0.004）和病变完全愈合（P= 0.038）方面加速;这三个参数的人群间中位时间差异平均为6天。在进入试验后，安慰剂接受者的疱疹病变表面积继续扩大;相反，药物接受者的病变表面积在治疗期间进行性减少。愈合速度受病变大小的影响。病变<50 mm 2的患者从治疗中获益最多，特别是在疼痛缓解和完全愈合时间方面（组间差异中位数为8天）。无论基础疾病、性别、既往化疗或年龄如何，阿昔洛韦治疗均具有临床获益。未发生临床或实验室不良反应。
Sixty-three immunocompromised patients with infections caused by herpes simplex virus were evaluated in a double-blind, placebo-controlled study of topical acyclovir therapy; 33 patients received acyclovir and 30 received the placebo. The two populations of patients were balanced in terms of age, race, sex, underlying disease, preceding chemotherapy, and site, size, and duration of lesions. Acyclovir recipients experienced an acceleration in the clearance of virus (P= .0006), the resolution of pain (P= .004), and the total healing of lesions (P= .038); median temporal differences between populations averaged six days for each of these three parameters. The surface area of herpetic lesions continued to enlarge in placebo recipients after entry into the trial; in contrast, lesion surface area decreased progressively during therapy in drug recipients. The speed of healing was influenced by lesion size. Patients with lesions of ⩾ 50 mm2benefited most from therapy, particularly in terms of pain resolution and time to total healing (median differences between groups, eight days). Irrespective of underlying disease, sex, preceding chemotherapy, or age, acyclovir therapy was of clinical benefit. No adverse clinical or laboratory reactions were encountered.